Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer

Clinical Drug Investigation

Volumn 21, Issue 3, 2001, Pages 161-168

  Schuette, W ^a   Bork, I ^b   Wollschlager B ^b   Schadlich S ^a  

^a City Hospital Martha Maria   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035095069     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121030-00001     Document Type: Article

References (5)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909
2. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-94
3. Bunn Jr PA. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 1989; 16: 27-33
4. Bunn Jr PA. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1989; 16: 10-21
5. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-41